Latest news
Apogee Therapeutics Positive Interim Results From Phase 1b Trial Of Zumilokibart (APG777) | Jan 06 Gorton School Lockdown (mvSdngPTwI) - MshaleMshale · Tue, 11 Aug 2026 06:04:47 GMTAPGE SWOT Analysis: Financial Resilience Amidst Clinical Challenges Revealed in 10-Q Filing - GuruFocusGuruFocus · Tue, 11 Aug 2026 04:52:58 GMTApogee Therapeutics Reports Q2 2026 Results and Announces Merger Agreement with AbbVie Subsidiary - Kalkine MediaKalkine Media · Mon, 10 Aug 2026 13:59:48 GMTApogee Therapeutics 2Q 2026: Net loss $85.9M, First half loss $160M — 10-Q Summary - TradingViewTradingView · Mon, 10 Aug 2026 12:01:01 GMTApogee Therapeutics (APGE) details Q2 2026 losses, AbbVie merger plan and $100M BXLS deal - Stock TitanStock Titan · Mon, 10 Aug 2026 11:53:11 GMTApogee Therapeutics (NASDAQ:APGE) Issues Earnings Results, Misses Expectations By $1.00 EPS - MarketBeatMarketBeat · Mon, 10 Aug 2026 11:41:44 GMTApogee Therapeutics reports Q2 2026 results; cash and marketable securities $1.3B, net loss $85.9M - TradingViewTradingView · Mon, 10 Aug 2026 11:23:01 GMTApogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates - GlobeNewswireGlobeNewswire · Mon, 10 Aug 2026 11:00:00 GMT